Cite
HARVARD Citation
Surampudi, U. et al. (n.d.). KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers. European journal of cancer. pp. S56-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Surampudi, U. et al. (n.d.). KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers. European journal of cancer. pp. S56-. [Online].